abs20.txt	purpose		to	investigate	the	implications	of	a	cancer	diagnosis	on	medicationadherence	for	pre-existing	comorbid	conditions	we	explored	statin	adherencepatterns	prior	and	following	new	breast	colorectal	orprostate	among	multi-ethnic	cohort	methods	identified	adults	enrolled	at	kaiser	permanente	northern	californiawho	were	prevalent	medication	users	newly	diagnosed	with	or	prostate	between	2000	2012	adherence	wasmeasured	using	proportion	days	covered	(pdc)	during	2-year	pre-cancerdiagnosis	post-cancer	patterns	assessedusing	generalized	estimating	equations	all	cancers	combined	stratifiedby	type	race/ethnicity	adjusted	demographic	clinical	tumorcharacteristics	results	10	177	patients	decreased	from	pre-	topost-cancer	(adjusted	odds	ratio	(oradj)	0	91	95%	confidence	interval(95%	ci)	88-0	94)	post-cancerdiagnosis	(oradj	94	ci	90-0	99)	79	74-0	85)	no	difference	in	was	observed	amongprostate	1	01	97-1	05)	cancerdiagnosis	statins	generally	higher	non-hispanic	whitesand	multi-race	than	other	groups	however	afterdiagnosis	only	these	two	populations	85	95%ci	85-0	92	oradj	86	76-0	97)	respectively	conclusions	found	substantial	variation	adherencefollowing	by	large	ofprevalent	an	integrated	health	care	setting	survivors	improving	our	understanding	comorbiditymanagement	polypharmacy	across	diverse	patient	iswarranted	develop	tailored	interventions	that	improve	andreduce	disparities	outcomes
